8-K: Vor Biopharma Implements 1-for-20 Reverse Stock Split

Vor Biopharma Inc. will implement a 1-for-20 reverse stock split effective September 18, 2025, to consolidate its common stock.

Summary

• Vor Biopharma Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split.
• The reverse stock split was authorized by stockholders at a Special Meeting on August 25, 2025.
• Effective at 5:00 p.m. Eastern Time on September 18, 2025, every 20 shares of common stock will convert into one share.
• The par value per share will not change.
• Proportionate adjustments will be made to the per share exercise price and number of shares for outstanding stock options and warrants.
• The number of shares reserved under the company's 2015 Stock Incentive Plan, Amended and Restated 2021 Equity Incentive Plan, 2021 Employee Stock Purchase Plan, and 2023 Inducement Plan will be reduced proportionately.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment.
• The reverse stock split will affect all stockholders proportionately and will not alter percentage ownership, except for fractional share cash-outs.
• Common stock will begin trading on The Nasdaq Global Select Market on a split-adjusted basis when the market opens on September 19, 2025.
• The new CUSIP number for the common stock will be 929033207.
• As of September 16, 2025, 136,822,693 shares of common stock were outstanding.
• Immediately following the reverse stock split, approximately 6,841,134 shares of common stock will be outstanding, subject to adjustment due to the effect of cashing out fractional shares.

Sentiment

Score: 4

Explanation: A reverse stock split is a mechanical corporate action often undertaken to meet exchange listing requirements or improve stock perception. While it doesn't change fundamental value, it typically follows a period of sustained low stock price, which can be viewed as a negative indicator of past performance or market sentiment.

Future Outlook

No explicit forward-looking statements or guidance were provided beyond the effective date and trading commencement of the reverse stock split.

Industry Context

The filing does not provide specific industry context or relate this corporate action to broader industry trends or competitors.

Corporate Governance

Stakeholder Impact

• Shareholders will own fewer shares of common stock, but each share will have a proportionally higher price, maintaining their overall equity value (excluding fractional share cash-outs).
• Holders of stock options and warrants will see their exercise prices increase and the number of shares issuable upon exercise decrease proportionally.
• Participants in equity incentive plans will have the number of shares reserved for issuance under those plans reduced proportionally.

Next Steps

• Common stock will begin trading on The Nasdaq Global Select Market on a split-adjusted basis on September 19, 2025.
• Stockholders entitled to fractional shares will receive a cash payment in lieu thereof.

Key Dates

Recommendation

The reverse stock split is a mechanical adjustment to the company's capital structure, primarily aimed at increasing the per-share trading price, often to meet exchange listing requirements. It does not fundamentally alter the company's underlying business operations, financial health, or long-term prospects. Therefore, it does not warrant a change in investment thesis based solely on this corporate action. Investors should 'hold' and continue to evaluate the company based on its clinical pipeline, financial performance, and strategic developments.

Keywords

Vor Biopharma, reverse stock split, common stock, Nasdaq, corporate action, stock consolidation, equity incentive plan, warrants, stock options